 |
 |
|
|
Technology | Programs | Pipeline | Collaborations | About Us | Contact Us |
 |
|
|
Oncology
Oncology
|
 |
Non-small Cell Lung Cancer
PKC Inhibition
Ras Pathway
|
|
Pancreatic Cancer
Ras Pathway |
|
Malignant Melanoma
RTKI |
|
|
|
|
Unmet Need - Cancer is the second leading cause of death in the U.S. According to the American Cancer Society, approximately 1 million new cases of cancer are diagnosed each year. The National Cancer Institute estimates annual direct medical costs for cancer treatment to be $40 billion in the United States.
Our Approach - Medisyn has discovered a series of potent inhibitors of PKC, RAS and RTKI pathways. These compounds display activity across a wide range of tumor types with potencies superior to current clinical stage compounds.
Pipeline Highlights:
Non small Cell Lung (NSCLC)
MT103 is a novel drug with potential application for treatment of PKC modulated cancers. In studies, MT103 preferentially inhibited the proliferation of NSCLC cell lines and induced apoptosis. MT103 was well tolerated in in vivo studies and compared favorably against other cancer treatment benchmarks .
Pancreatic / NSCLC | Available for Licensing >>
MT477 is a novel quinoline with potential application for treatment of Ras-mutated cancers. In recent in vivo studies, MT477 preferentially inhibited the proliferation of K-ras-mutated human pulmonary and pancreatic adenocarcinoma cell lines, induced apoptosis, is associated with caspase-3 activation, and induced sub-G1 cell-cycle arrest. MT477 is active in Ras-mutated cancers as well as non-Ras mutated cancers and could be developed extensively as an anticancer drug lead.
Malignant Melanoma
MT062 is a novel lead with potential application for treatment of RTKI pathway cancers. In studies, MT062 was found to be a selective and potent EGFR inhibitor. |
|
|
|
|
|
|
|
|
|
 |
